Development of an automated AAV capsid titer assay on a high-throughput platform

Matt Lotti is a Senior Research Associate II at Ultragenyx Pharmaceutical Inc., with over 15 years in biotechnology and marine science. Specializing in biotechnology/microbiology analytical method development, he excels in gene therapy, impurities analysis, and stability studies management. His extensive experience spans roles at Pfizer, Aushon BioSystems, and NOAA, among others. With a strong background in teaching and public outreach, Matt is dedicated to advancing scientific research and education.

John Chappell has approximately 25 years of experience in the Contract Research industry supporting both preclinical and clinical drug development. He has specialized in supporting biological compounds from an analytical perspective e.g., pharmacokinetic, immunogenicity and biomarker analysis. He is particularly interested in validation requirements and ensuring that data generated will be acceptable to the regulatory authorities.

He has spoken at many international conferences on various topics including oligonucleotide analysis, biomarker analysis, immunogenicity and the analytical support of biosimilar programs.

John is currently Sr Global Scientific Support Manager for Gyros Protein Technologies where he is responsible for training the Field Application Team as well as implementing customer collaborations and scientific innovations. John has been a user of the Gyrolab system for over 10 years.

As a Fellow of the Royal Society of Chemistry, he was involved in the American Association of Pharmaceutical Scientists (AAPS) Biosimilar Committee that has published papers on Pharmacokinetic and anti-drug antibody assays.